Researchers open up possible avenue for new cancer treatments without side effects

Researchers have opened up a possible avenue for new cancer therapies that don't have the side effects that oftentimes accompany many current cancer treatments by identifying a protein modification that specifically supports proliferation and survival of tumor cells.

Depending on the kind of cancer and the type of treatment, a patient might suffer from many side effects, including anemia, loss of appetite, bleeding, bruising, constipation, delirium, diarrhea, fatigue, hair loss, nausea, sexual issues or bladder problems.

Scientists at Oregon State University, the University of Central Florida and New York University made the protein-modification discovery while studying neurofibromatosis type 2. The condition, commonly known as NF2, is characterized by the development of tumors of the nervous system called schwannomas.

The hallmark of tumor cell behavior is their uncontrolled growth. Tumors cells need to constantly produce energy and building blocks to replicate."

Maca Franco, professor of biochemistry and biophysics, OSU's College of Science

Researchers led by Franco and Oregon State undergraduate student Jeanine Pestoni found that schwannoma cells produce an oxidant and nitrating agent, peroxynitrite, which modifies an amino acid, tyrosine, in proteins.

When tyrosine becomes nitrated in specific proteins, an effect is the reprogramming of the tumor cells' metabolism, enabling them to proliferate.

"To sustain persistent growth, tumor cells change the way they produce energy and building blocks and present a signature metabolic phenotype that differs from that of normal cells," Franco said. "We discovered that peroxynitrite, the most powerful oxidant produced by cells, controls the metabolic changes that occur in tumor cells of the nervous system and supports their growth. We believe that there are specific proteins that when they become nitrated acquire a new function they did not have before, and this new function may control tumor growth."

Peroxynitrite is produced at high levels in "pathological conditions," she said - such as those found in tumors - but not in normal tissues.

"This opens up the exciting possibility of targeting peroxynitrite production exclusively in tumor cells as a new therapeutic strategy for the treatment of tumors of the nervous system, with minimal to no side effects on normal tissues," Franco added. "We are uncovering a completely new category of targets for the treatment of solid tumors, and not only tumors of the nervous system - it may have broader implications for the treatment of several cancer types. We can go after proteins that usually aren't modified in normal cells; we can target those modified proteins with inhibitors that don't affect normal cells, hopefully developing a treatment with minimal side effects."

Source:
Journal reference:

Peston, J.C. et al. (2019) Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival. Journal of Biological Chemistry. doi.org/10.1074/jbc.RA118.007152.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers reveal mechanisms of how CDK12 alterations drive prostate cancer development